Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Increase in finite-lived intangible assets		$ 37,492	$ 35,664
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Increase in finite-lived intangible assets	[1]	35,625	$ 33,740
Eucrisa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Transfer of intangible assets during period		4,800
Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Increase in finite-lived intangible assets		371
In Process Research and Development [Member] | Eucrisa [Member]
Finite-Lived Intangible Assets [Line Items]
Transfer of intangible assets during period		$ (4,800)

[1] The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A) and (v) impairments of Developed technology rights (see Note 4).